Skip to Main Content

Paper Details

The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence.
Ann Intern Med
2
2023
Author NameAffiliation
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Harvard Medical School
  • 1 - 1

Datasets

Release 1.2